


Volume 44 Supplement 1 April 2019 ISSN 0960 9776

IN THIS SUPPLEMENT  
PRIMARY THERAPY OF EARLY BREAST CANCER  
16TH ST.GALLEN INTERNATIONAL BREAST CANCER CONFERENCE  
VIENNA, AUSTRIA, 20-23 MARCH 2019

# THE BREAST

An Associate Journal of the Australasian Society for Breast Disease  
Affiliated with the European Society of Breast Cancer Specialists  
Official Journal of the Breast Centres Network



Publication of this Abstract Book is sponsored by St. Gallen Oncology Conferences

# THE BREAST

## PRIMARY THERAPY OF EARLY BREAST CANCER

**Evidence, Controversies, Consensus**

**16<sup>th</sup> St.Gallen International Breast Cancer Conference  
Vienna/Austria, 20–23 March 2019**

**Estimating the Magnitude of Clinical Benefit**

### **Organising and Scientific chairs**

Harold J. Burstein (USA)

Marco Colleoni (Italy)

Giuseppe Curigliano (Italy)

Carsten Denkert (Germany)

Peter Dubsy (Switzerland)

Michael Gnant (Austria)

Sibylle Loibl (Germany)

Martine Piccart-Gebhart (Belgium)

Philip Poortmans (The Netherlands/France)

Meredith Regan (USA)

Hans-Jörg Senn (Switzerland)

Beat Thürlimann (Switzerland)

Eric P. Winer (USA)

Publication of this Abstract Book is sponsored by St. Gallen Oncology Conferences

# THE BREAST

## Editor-in-Chief

**Fatima Cardoso**, Champalimaud Clinical Centre, Lisbon, Portugal

## Co-Editors

**Nehmat Houssami**, University of Sydney, Sydney, Australia

**Giuseppe Curigliano**, University of Milano, European Institute of Oncology, Milan, Italy

## Epidemiology and prevention:

**Imaging, screening and early diagnosis:**

**Familial and Hereditary Breast Cancer:**

**Pathology:**

**Surgery and Oncoplastic Surgery:**

**Medical oncology:**

**Radiation Oncology:**

**Translational Research:**

**Psycho-oncology:**

**Quality of Life and Survivorship:**

## Specialty Editor

**E. Negri**, Milan, Italy

**N. Houssami**, Sydney, Australia

**S. Delaloge**, Paris, France

**G. Pruneri**, Milan, Italy

**M.J. Cardoso**, Lisbon, Portugal

**O. Gentilini**, Milan, Italy

**E. Senkus-Konefka**, Gdansk, Poland

**P. Francis**, Melbourne, Australia

**P. Poortmans**, Paris, France

**S. Di Cosimo**, Milan, Italy

**G. Pravettoni**, Milan, Italy

**K. Ruddy**, Rochester, USA

**Australasian Society for Breast Disease Representative**

**E. Elder** New South Wales, Australia

**EUSOMA – European Society of Breast Cancer Specialists Representative**

**C. Markopoulos** Athens, Greece

**St Gallen Conferences Oncology Representatives**

**B. Thürlimann** St Gallen, Switzerland

**H.J. Senn** St Gallen, Switzerland

**Breast Centres Network Representative**

**C. Tinterri** Milan, Italy

## International Advisory Board

**B. Anderson** Seattle, USA

**F. André** Villejuif, France

**B. Arun** Houston, Texas, USA

**H.A. Azim** Marseille, France

**G.S. Bhattacharyya** West Bengal, India

**G. de Bock** Groningen, The Netherlands

**J. Bogaerts** Brussels, Belgium

**E. Brain** Saint-Cloud, France

**M. Brennan** Sydney, Australia

**R.E. Coleman** Sheffield, UK

**J. Cortes** Barcelona, Spain

**A. Costa** Milan, Italy

**T. Cufer** Ljubljana, Slovenia

**R. Dent** Prato, Italy

**J. M. Dixon** Edinburgh, Scotland

**S. Duffy** London, UK

**L.E.M. Duijm** Nijmegen, Netherlands

**N. El Saghir** Beirut, Lebanon

**W. Gatzemeier** Milan, Italy

**P. Ganz** Los Angeles, USA

**J. Gligorov** Paris, France

**J. Harris** Boston, USA

**S. Hurvitz** Santa Monica, USA

**G. Jerusalem** Liège, Belgium

**B. Kaufman** Ramat Gan, Israel

**H. de Koning** Eindhoven, The Netherlands

**S. Kyriakides** Nicosia, Cyprus

**A. Di Leo** Prato, Italy

**B. Linderholm** Gothenburg, Sweden

**L. Lusa** Ljubljana, Slovenia

**B. Mann** Parkville, Australia

**S. Nakamura** Tokyo, Japan

**S. Ohno** Fukuoka, Japan

**M. Paesmans** Brussels, Belgium

**O. Pagani** Lugano, Switzerland

**A. Partridge** Boston, USA

**F.A. Peccatori** Milan, Italy

**F. Penault-Llorca** Clermont-Ferrand, France

**G. Pravettoni** Milan, Italy

**K. Pritchard** Toronto, Canada

**M.M. Regan** Boston, Massachusetts, USA

**I. Rubio** Barcelona, Spain

**V. Sacchini** New York, NY, USA

**K. Sandelin** Stockholm, Sweden

**F. Sardanelli** Milan, Italy

**G. Schwartzmann** Porto Alegre, Brazil

**V. Semiglazov** St. Petersburg, Russia

**L. Solin** Philadelphia, USA

**V. Speirs** Leeds, UK

**E. Tagliabue** Milan, Italy

**A. Tagliafico** Genova, Italy

**D.A. Vorobiof** Johannesburg, S.A.

**M.G. Wallis** Cambridge, UK

**N. Williams** London, UK

**B. Xu** Beijing, China

**Y. Yarden** Tel Aviv, Israel

**S. Zackrisson** Malmö, Sweden

**J. Žgajnar** Ljubljana, Slovenia



ELSEVIER

<http://www.thebreastonline.com>

An Associate Journal of the Australasian Society for Breast Disease: [www.asbd.org.au](http://www.asbd.org.au)

Affiliated with the European Society of Breast Cancer Specialists: [www.eusoma.org](http://www.eusoma.org)

Official Journal of Breast Centres Network: [www.BreastCentresNetwork.org](http://www.BreastCentresNetwork.org)

Amsterdam . Boston . London . New York . Oxford . Paris . Philadelphia .

San Diego . St Louis

## The Breast: Aims and Scope

*The Breast* is an international, multidisciplinary journal for researchers and clinicians, which focuses on translational and clinical research for the advancement of breast cancer prevention, diagnosis and treatment of all stages. The Editors welcome the submission of original research articles, systematic reviews, and viewpoint/commentary and debate articles, and correspondence on all areas of pre-malignant and malignant breast disease, including:

- Epidemiology and prevention
- Translational research, encompassing the use of new technologies, molecular biology, genetics and pathology
- Screening, early diagnosis, follow-up and response assessment: use of imaging, nuclear medicine and other technologies
- Medical oncology
- Radiation oncology
- Breast surgery
- Psycho-oncology
- Quality of life
- Survivorship
- Supportive care
- Palliative and end-of-life care
- Advocacy
- Breast Nursing
- Breast Units management and organization of breast care, including health economics

---

### Author enquiries

You can track your submitted article at <http://www.elsevier.com/track-submission>. You can track your accepted article at <http://www.elsevier.com/trackarticle>. You are also welcome to contact Customer Support via <http://support.elsevier.com>.

**Publication information.** *The Breast* (ISSN 0960-9776). For 2019, volumes 43–48 (6 issues) are scheduled for publication. Subscription prices are available upon request from the Publisher or from the Elsevier Customer Service Department nearest you or from this journal's website (<http://www.elsevier.com/brst>). Further information is available on this journal and other Elsevier products through Elsevier's website: (<http://www.elsevier.com>). Subscriptions are accepted on a prepaid basis only and are entered on a calendar year basis. Issues are sent by standard mail (surface within Europe, air delivery outside Europe). Priority rates are available upon request. Claims for missing issues should be made within six months of the date of dispatch.

**Orders, claims, and journal inquiries:** Please visit our Support Hub page <https://service.elsevier.com> for assistance.

**USA mailing notice:** *The Breast* (ISSN 0960-9776) is published bimonthly by Elsevier Ltd. (P.O. Box 211, 1000 AE Amsterdam, The Netherlands). Periodicals postage paid at Jamaica, NY 11431 and additional mailing offices.

**USA POSTMASTER:** Send address changes to *The Breast*, Elsevier, Journal Returns, 1799 Highway 50 East, Linn, MO 65051, USA.

**AIRFREIGHT AND MAILING** in USA by Air Business Ltd., c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.

Copyright © 2019 Elsevier Ltd. All rights reserved.

This journal and the individual contributions contained in it are protected under copyright by Elsevier Ltd., and the following terms and conditions apply to their use:

### Photocopying

Single photocopies of single articles may be made for personal use as allowed by national copyright laws. Permission of the Publisher and payment of a fee is required for all other photocopying, including multiple or systematic copying, copying for advertising or promotional purposes, resale, and all forms of document delivery. Special rates are available for educational institutions that wish to make photocopies for non-profit educational classroom use.

Permissions may be sought directly from Elsevier's Rights Department in Philadelphia, PA, USA; phone: (+1) 215 238 7869, fax: (+1) 215 238 2239, e-mail: [healthpermissions@elsevier.com](mailto:healthpermissions@elsevier.com). Requests may also be completed on-line via the Elsevier homepage (<http://www.elsevier.com/locate/permissions>).

In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA; phone: (+1) (978) 7508400, fax: (+1) (978) 7504744, and in the UK through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK; phone: (+44) 20 7631 5555; fax: (+44) 20 7631 5500. Other countries may have a local reprographic rights agency for payments.

### Derivative Works

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the publisher is required for resale or distribution outside the institution.

Permission of the publisher is required for all other derivative works, including compilations and translations.

### Electronic Storage or Usage

Permission of the publisher is required to store or use electronically any material contained in this journal, including any article or part of an article.

Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the Publisher.

Address permissions requests to: Elsevier Rights Department, at the fax and e-mail addresses noted above.

### Funding Body Agreements and Policies

Elsevier has established agreements and developed policies to allow authors whose articles appear in journals published by Elsevier, to comply with potential manuscript archiving requirements as specified as conditions of their grant awards. To learn more about existing agreements and policies please visit <http://www.elsevier.com/fundingbodies>.

### Notice

No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made.

Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.

### Language (usage and editing services)

Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service available from Elsevier's WebShop <http://webshop.elsevier.com/languageediting/> or visit our customer support site <http://support.elsevier.com> for more information.

### Illustration services

Elsevier's WebShop (<http://webshop.elsevier.com/illustrationservices>) offers Illustration Services to authors preparing to submit a manuscript but concerned about the quality of the images accompanying their article. Elsevier's expert illustrators can produce scientific, technical and medical-style images, as well as a full range of charts, tables and graphs. Image 'polishing' is also available, where our illustrators take your image(s) and improve them to a professional standard. Please visit the website to find out more.

---

*The Breast* has no page charges.

©The paper used in this publication meets the requirements of ANSI/NISO Z39.48-1992 (Permanence of Paper).

Printed in the United Kingdom by Henry Ling Limited, at the Dorset Press, Dorchester, DT1 1HD.



**BCC 2021**

# 17<sup>th</sup> St. Gallen International Breast Cancer Conference 2021

Primary Therapy of Early Breast Cancer  
Evidence, Controversies, Consensus

17–20 March 2021, Vienna/Austria

**First Announcement 2021**



## First Announcement

### Information

St.Gallen Oncology Conferences (SONK)  
c/o Tumor and Breast Center ZeTuP  
Rorschacherstrasse 150  
CH-9006 St.Gallen/Switzerland  
[info@oncoconferences.ch](mailto:info@oncoconferences.ch)  
[www.oncoconferences.ch](http://www.oncoconferences.ch)

VOLUME 44 S1 APRIL 2019

# THE BREAST

---

## Speakers' Abstracts

### Wednesday, 20 March 2019

Award Lecture by the St.Gallen 2019 Award Winner (Prof. Monica Morrow)	S1
Award Lecture by the ESO Umberto Veronesi Memorial Award Winner (Dame Lesley Fallowfield)	S1
Session 1: News since St.Gallen 2017	S1
Session 2: Biology of breast cancer I: Risk stratification	S2

### Thursday, 21 March 2019

Session 3: Biology of breast cancer II: Prediction of response	S3
Session 4: Risk stratification and prevention in ductal in situ carcinoma	S5
Special Lecture I and II	S6
Session 5: New pathways with potential impact in the treatment of early breast cancer	S6
Session 6: Treatment tailoring according to pathology and biology	S7

### Friday, 22 March 2019

Session 7: Surgery of early breast cancer	S8
Session 8: Radiotherapy of early breast cancer	S9
Special Lecture III	S11
Session 9: Primary and adjuvant systemic therapy of early breast cancer: Estimating the magnitude of clinical benefit I	S11
Session 10: Primary and adjuvant systemic therapy of early breast cancer: Estimating the magnitude of clinical benefit II	S12

## Poster Abstracts I

Adjuvant systemic therapy	S15
Biology/Pathology/Basic Research	S24
Epidemiology/Prevention/Diagnosis	S40
Locally advanced and metastatic disease	S57
Neoadjuvant (pre-operative) therapy	S66

## Poster Abstracts II

Radiotherapy/IORT	S79
Health politics/Guidelines	S86
Predictive and prognostic factors	S88
Surgery/Sentinels/DCIS	S104
Other	S125

## Author Index

S143

### Guide for Authors

Submission to *The Breast* proceeds totally online via the Elsevier Editorial System page of this journal at <http://ees.elsevier.com/thebreast/>. Authors will be guided through the creation and uploading of the various files. Once the uploading is done, the system automatically generates an electronic (PDF) proof, which is then used for reviewing. All correspondence, including the Editor's decision and request for revisions, will be by e-mail. Authors may send queries concerning the submission process, manuscript status, or journal procedures to the editorial office at [thebreast@elsevier.com](mailto:thebreast@elsevier.com)

Available online at [www.sciencedirect.com](http://www.sciencedirect.com)

## ScienceDirect

Indexed/abstracted in: *Index Medicus, MEDLINE, ABI/Inform, Current Awareness in Biological Sciences, Current Contents/Clinical Medicine, EMBASE, Excerpta Medica National Library of Medicine (MEDLARS and MEDLINE), Research Alert, SCISEARCH, Science Citation Index Expanded, Scopus*



ELSEVIER

Amsterdam . Boston . London . New York . Oxford .  
Paris . Philadelphia . San Diego . St Louis

## Predictive and prognostic factors

### P209

#### Mammographic breast density: visual and automated measurement, its role in tumor size and prognostic factors

M. Izquierdo\*, J. Browne, S. Garcia, F. Tresserra, M. Garcia, S. Baulies, C. Ara, M.A. Pascual, R. Fabregas, Hospital Universitari Dexeus Barcelona, Spain

**Goals:** Study the visual and automatic measurement of mammographic breast density and its implications as a prognostic factor.

**Methods:** Study the visual and automatic measurement of mammographic breast density according to the breast imaging data system (BI-RADS) in 212 patients with invasive unifocal breast cancer (not microinvasive) who did not perform neoadjuvant chemotherapy and surgery before.

Analyze the tumor size globally and with the BIRADS mammographic breast density categories, comparing the histological tumor size, versus the clinical size, ultrasound size, mammographic size and size of the magnetic resonance, a regression is made to study which test values the size better, and the correlation of DMR with prognostic factors (RE, RP, HER2, Ki67, p53).

**Results:** The comparison of Visual DMR and Automatic DMR, visual DMR 2 the DMR Automatic matches in 40.6% (41/101), in 58.4% (59/101) the DMR is 1, the visual DMR 3 matches with DMR 3 automatic in 32.1% (9/28), in the DMR 3 automatic 64.3% (18/28) is lower ( $p < 0.001$ ). When comparing Visual DMR and Automatic DMR, visual DMR 2 the DMR Automatic matches in 40.6% (41/101), in 58.4% (59/101) the DMR is 1, the visual DMR 3 matches with DMR 3 automatic in 32.1% (9/28), in the DMR 3 automatic 64.3% (18/28) is lower ( $p < 0.001$ ). The study of BMI with DMR, a BMI > 30 there are 0 cases DMR BIRADS 4 (visual and automatic), BMI 15–29.9 there are 0 cases DMR BIRADS 4 automated and 4 cases (14.8%) with DMR BIRADS 4 visual. DMR is not correlated ( $p = ns$ ) with prognostic factors (ER, PR, HER2, Ki67, Histological Grade). The study of size using linear regression shows us a better estimate with less variability with ultrasound and magnetic resonance. ( $\bar{x} + 1.96 \sigma$ )

**Conclusions:** Visual measurement overestimate MBD versus automatic measurement according BIRADS categories. Ultrasound and magnetic resonance estimate tumor size better with less variability. MBD is not related to tumor prognostic factors.

**Conflict of Interest:** No significant relationships.

### P210

#### The mathematical model for predicting the earliest diagnostics period of the secondary distant metastases growth process of breast cancer

E. Tyuryumina\*, A. Neznanov. International Laboratory for Intelligent Systems and Structural Analysis, National Research University Higher School of Economics, Moscow, Russian Federation

**Goals:** Previously, the mathematical models (CoMPaS and CoM-III) of primary tumor (PT) growth and secondary distant metastases (sdMTS) growth of breast cancer (BC) considering TNM classification have been presented (Tyuryumina E., Neznanov A.; 2017, 2018).

**Goal:** To detect the earliest diagnostics period of visible sdMTS via CoMPaS and CoM-III.

**Methods:** The models CoMPaS and CoM-III rest on exponential growth model and complementing formulas and correspond to TNM classification. The CoMPaS and CoM-III allow for calculating: (1) the tumor volume doubling time (TVDT) of the PT and the sdMTS (CoMPaS); (2) the correction coefficient of the sdMTS spreading rate in patients with lymph node MTS related with the PT growth rate (CoM-III); (3) the earliest diagnostics periods of the sdMTS. The CoMPaS model reflects the stages I-II (T1-3N0M0), the growth processes of PT and sdMTS in BC patients **without** lymph nodes MTS. The CoM-III describes the stages II-III (T1-3N1-3M0), the growth processes of PT and sdMTS in BC patients **with** lymph nodes MTS.

**Results:** The critical growth periods have been defined via the models CoMPaS and CoM-III: (1) the non-visible growth period of PT of BC; (2) the non-visible growth period of sdMTS of BC; (3) the visible growth period of sdMTS of BC. The CoMPaS and CoM-III correctly describe the growth period of PT and corresponds to TNM classification (parameter T), the growth period of the sdMTS (parameter M) and the 10–15-year survival of BC patients considering TNM classification. The CoMPaS correctly describes the growth of PT in BC patients with T1-3N0M0 stages and helps to calculate the period in which the sdMTS might appear (M1). The CoM-III correctly describes the growth of PT in BC patients with T1-3N1-3M0 stages and helps to calculate the period in which the sdMTS might appear (M1).

**Conclusions:** The models CoMPaS and CoM-III and the corresponded software tool can help: (1) to optimise the process of detecting the earliest diagnostics periods of sdMTS in BC patients (T1-3N0-3M0) considering TNM classification and the growth rate of PT and sdMTS of BC; (2) to improve the effectiveness of the earliest diagnostics and to start the earliest treatment of small sdMTS in BC patients (T1-3N0-3M0); (3) to increase the survival of BC patients with sdMTS (T1-3N0-3M0).

**Conflict of Interest:** No significant relationships.

### P211

#### Integration of whole-genome sequencing and functional screening identifies a prognostic signature for lung metastasis in triple-negative breast cancer

G. Xie<sup>1\*</sup>, H. Yang<sup>1</sup>, D. Ma<sup>1</sup>, Y. Sun<sup>2</sup>, H. Chen<sup>2</sup>, X. Hu<sup>1</sup>, Y. Jiang<sup>1</sup>, Z. Shao<sup>1,3</sup>. <sup>1</sup>Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China, <sup>2</sup>Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China, <sup>3</sup>Institutes of Biomedical Sciences, Fudan University Shanghai Cancer Center, Shanghai, China

**Goals:** Lung metastasis is one of the leading causes of death for triple-negative breast cancer (TNBC). We sought to characterize the genetic alterations underlying TNBC lung metastases by integrating whole-genome sequencing and functional screening. Further, we aimed to develop a metastasis-related gene signature for TNBC patients to improve risk stratification.

**Methods:** In this prospective observational study, we first conducted whole-genome sequencing of paired primary tumor and lung metastasis from one TNBC patient to identify potential genetic driver alterations. An *in vivo* gain-of-function screening using an amplified open reading frame library was then employed to screen candidate genes promoting lung metastasis. Finally, we applied Cox proportional hazard regression modeling to develop a prognostic gene signature from 14 candidate genes in TNBC.

**Results:** Compared with the primary tumor, copy number amplifications of chromosomes 3q and 8q were identified in the lung metastasis. We discovered an enrichment of 14 genes from chromosomes 3q and 8q in mouse lung metastases model. We further developed and validated a four-gene signature (*ENY2*, *KCNK9*, *TNFRSF11B* and *KCNMB2*) that predicts recurrence-free survival and lung metastasis in TNBC. Our data also demonstrated that upregulated expression of *ENY2* could promote invasion and lung metastasis of TNBC cells both *in vitro* and *in vivo*.

**Conclusions:** In conclusion, our study reveals functional genes with copy number amplifications among chromosome 3q and 8q in lung metastasis of TNBC. And we develop a functional gene signature that can effectively stratify patients into low- and high-risk subgroups of recurrence, helping frame personalized treatments for TNBC.

**Conflict of Interest:** No significant relationships.